Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

Ozempic is only licensed for Type 2 diabetes patients in the UK (though some doctors prescribe it off-label for weight loss), while Wegovy has ... The bar chart below compares the rate of NAION ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024 but its manufacturer has predicted growth will slow this year. Novo Nordisk's rise to become one of Europe's ...

The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, were key to its earnings beat. Combined, they brought in $24.9 billion for the year. That's compared ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...

Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled ... in 2025 to further explore CagriSema’s weight-loss potential. The results from the second ...